• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用碱基编辑器直接校正血红蛋白 E β-地中海贫血。

Direct correction of haemoglobin E β-thalassaemia using base editors.

机构信息

MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, UK.

出版信息

Nat Commun. 2023 Apr 19;14(1):2238. doi: 10.1038/s41467-023-37604-8.

DOI:10.1038/s41467-023-37604-8
PMID:37076455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10115876/
Abstract

Haemoglobin E (HbE) β-thalassaemia causes approximately 50% of all severe thalassaemia worldwide; equating to around 30,000 births per year. HbE β-thalassaemia is due to a point mutation in codon 26 of the human HBB gene on one allele (GAG; glutamatic acid → AAG; lysine, E26K), and any mutation causing severe β-thalassaemia on the other. When inherited together in compound heterozygosity these mutations can cause a severe thalassaemic phenotype. However, if only one allele is mutated individuals are carriers for the respective mutation and have an asymptomatic phenotype (β-thalassaemia trait). Here we describe a base editing strategy which corrects the HbE mutation either to wildtype (WT) or a normal variant haemoglobin (E26G) known as Hb Aubenas and thereby recreates the asymptomatic trait phenotype. We have achieved editing efficiencies in excess of 90% in primary human CD34 + cells. We demonstrate editing of long-term repopulating haematopoietic stem cells (LT-HSCs) using serial xenotransplantation in NSG mice. We have profiled the off-target effects using a combination of circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq) and deep targeted capture and have developed machine-learning based methods to predict functional effects of candidate off-target mutations.

摘要

血红蛋白 E (HbE) β-地中海贫血症导致全球约 50%的严重地中海贫血症;相当于每年约有 3 万人出生。HbE β-地中海贫血症是由于人类 HBB 基因一个等位基因上的密码子 26 发生点突变(GAG;谷氨酸→AAG;赖氨酸,E26K),以及另一个等位基因上导致严重β-地中海贫血症的任何突变。当这些突变在复合杂合子中遗传时,它们可能导致严重的地中海贫血表型。然而,如果只有一个等位基因发生突变,个体则为相应突变的携带者,表现为无症状表型(β-地中海贫血特征)。在这里,我们描述了一种碱基编辑策略,可以将 HbE 突变校正为野生型(WT)或一种称为 Hb Aubenas 的正常变异血红蛋白(E26G),从而再现无症状特征表型。我们在原代人 CD34+细胞中实现了超过 90%的编辑效率。我们使用 NSG 小鼠的连续异种移植证明了对长期重造血干细胞(LT-HSCs)的编辑。我们使用结合测序的环化(CIRCLE-seq)体外报告切割效应和深度靶向捕获来分析脱靶效应,并开发了基于机器学习的方法来预测候选脱靶突变的功能效应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30a/10115876/2f83ef4ee660/41467_2023_37604_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30a/10115876/837532ca752b/41467_2023_37604_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30a/10115876/2f83ef4ee660/41467_2023_37604_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30a/10115876/837532ca752b/41467_2023_37604_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30a/10115876/2f83ef4ee660/41467_2023_37604_Fig2_HTML.jpg

相似文献

1
Direct correction of haemoglobin E β-thalassaemia using base editors.使用碱基编辑器直接校正血红蛋白 E β-地中海贫血。
Nat Commun. 2023 Apr 19;14(1):2238. doi: 10.1038/s41467-023-37604-8.
2
Clinical expression of a rare beta-globin gene mutation co-inherited with haemoglobin E-disease.一种与血红蛋白E病共同遗传的罕见β-珠蛋白基因突变的临床表型。
Eur J Clin Chem Clin Biochem. 1996 Dec;34(12):949-54. doi: 10.1515/cclm.1996.34.12.949.
3
Molecular characterisation of haemoglobin E-Udon Thani (HBB:c.[79G>A;92+7A>G]): a novel form of Hb E-β-thalassaemia syndrome.血红蛋白 E-Udon Thani(HBB:c.[79G>A;92+7A>G])的分子特征:一种新型的血红蛋白 E-β-地中海贫血综合征。
J Clin Pathol. 2019 Apr;72(4):322-324. doi: 10.1136/jclinpath-2018-205525. Epub 2019 Jan 10.
4
Haemoglobinopathies in southeast Asia.东南亚的血红蛋白病。
Indian J Med Res. 2011 Oct;134(4):498-506.
5
Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.与输血依赖型 HbE-β 地中海贫血胎儿血红蛋白药物诱导相关的遗传决定因素。
Ann Hematol. 2019 Feb;98(2):289-299. doi: 10.1007/s00277-018-3536-x. Epub 2018 Nov 9.
6
Molecular Characterization and Hematological Aspects of Hb E-Myanmar [β26(B8)Glu→Lys and β65(E9)Lys→Asn, : c.[79G>A;198G>C]): A Novel β-Thalassemic Hemoglobin Variant.Hb E-缅甸 [β26(B8)Glu→Lys 和 β65(E9)Lys→Asn,: c.[79G>A;198G>C]): 一种新型β-地中海贫血血红蛋白变异体的分子特征和血液学方面。
Hemoglobin. 2020 Nov;44(6):385-390. doi: 10.1080/03630269.2020.1848860. Epub 2020 Nov 22.
7
Hb E/beta-thalassaemia: a common & clinically diverse disorder.Hb E/β-地中海贫血:一种常见且临床表现多样的疾病。
Indian J Med Res. 2011 Oct;134(4):522-31.
8
α-Haemoglobin stabilising protein expression is influenced by mean cell haemoglobin and HbF levels in HbE/β-thalassaemia individuals.α-血红蛋白稳定剂蛋白的表达受 HbE/β-地中海贫血个体中平均细胞血红蛋白和 HbF 水平的影响。
Blood Cells Mol Dis. 2012 Jan 15;48(1):17-21. doi: 10.1016/j.bcmd.2011.10.002. Epub 2011 Nov 12.
9
Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group.斯里兰卡的地中海贫血:对亚洲人群未来健康负担的影响。斯里兰卡地中海贫血研究小组。
Lancet. 2000 Mar 4;355(9206):786-91. doi: 10.1016/s0140-6736(99)08246-x.
10
The successful strategy of comprehensive pre-implantation genetic testing for beta-thalassaemia-haemoglobin E disease and chromosome balance using karyomapping.采用核型映射对β-地中海贫血-血红蛋白 E 病和染色体平衡进行综合植入前遗传检测的成功策略。
J Obstet Gynaecol. 2022 Aug;42(6):2433-2441. doi: 10.1080/01443615.2022.2070728. Epub 2022 Jun 2.

引用本文的文献

1
Advancing Precision Medicine: Recent Innovations in Gene Editing Technologies.推进精准医学:基因编辑技术的最新创新
Adv Sci (Weinh). 2025 Apr;12(14):e2410237. doi: 10.1002/advs.202410237. Epub 2025 Mar 2.
2
Combined heterozygosity for hemoglobin Paksé, α-thalassemia and for hemoglobin E, β- thalassemia ̵ first appearance in Europe.血红蛋白巴色、α地中海贫血以及血红蛋白E、β地中海贫血的联合杂合性——在欧洲首次出现。
Ann Hematol. 2025 Mar;104(3):2059-2064. doi: 10.1007/s00277-025-06286-1. Epub 2025 Feb 28.
3
Systematic empirical evaluation of individual base editing targets: Validating therapeutic targets in USH2A and comparison of methods.

本文引用的文献

1
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.鉴定 LZTFL1 为 COVID-19 风险位点的候选效应基因。
Nat Genet. 2021 Nov;53(11):1606-1615. doi: 10.1038/s41588-021-00955-3. Epub 2021 Nov 4.
2
Long Non-Coding RNA LINC01569 Promotes Proliferation and Metastasis in Colorectal Cancer by miR-381-3p/RAP2A Axis.长链非编码RNA LINC01569通过miR-381-3p/RAP2A轴促进结直肠癌的增殖和转移。
Front Oncol. 2021 Aug 6;11:727698. doi: 10.3389/fonc.2021.727698. eCollection 2021.
3
Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
对单个碱基编辑靶点的系统实证评估:验证USH2A中的治疗靶点及方法比较
Mol Ther. 2025 Apr 2;33(4):1466-1484. doi: 10.1016/j.ymthe.2025.01.042. Epub 2025 Jan 28.
4
Editing of homologous globin genes by nickase-deficient base editor mitigates large intergenic deletions in HSPCs.通过尼克酶缺陷型碱基编辑器对同源珠蛋白基因进行编辑可减轻造血干细胞中的大型基因间缺失。
Mol Ther Nucleic Acids. 2024 Sep 30;35(4):102347. doi: 10.1016/j.omtn.2024.102347. eCollection 2024 Dec 10.
5
CRISPR technology in human diseases.用于人类疾病治疗的CRISPR技术。
MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug.
6
Engineering strategies to safely drive CAR T-cells into the future.工程化策略助力 CAR T 细胞安全迈入未来。
Front Immunol. 2024 Jun 19;15:1411393. doi: 10.3389/fimmu.2024.1411393. eCollection 2024.
7
Precise correction of a spectrum of β-thalassemia mutations in coding and non-coding regions by base editors.通过碱基编辑器对编码区和非编码区一系列β地中海贫血突变进行精确校正。
Mol Ther Nucleic Acids. 2024 May 3;35(2):102205. doi: 10.1016/j.omtn.2024.102205. eCollection 2024 Jun 11.
8
Enhancing genome editing in hPSCs through dual inhibition of DNA damage response and repair pathways.通过双重抑制 DNA 损伤反应和修复途径来增强 hPSCs 中的基因组编辑。
Nat Commun. 2024 May 11;15(1):4002. doi: 10.1038/s41467-024-48111-9.
9
Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.去铁胺、地拉罗司和去铁酮三联铁螯合剂疗法治疗输血依赖型β-地中海贫血伴严重铁过载的疗效和安全性:一项随机对照临床试验方案。
BMJ Open. 2024 Feb 8;14(2):e077342. doi: 10.1136/bmjopen-2023-077342.
10
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.基于 CRISPR/Cas 的基因编辑在治疗β-地中海贫血症的策略中的应用。
Hum Genet. 2023 Dec;142(12):1677-1703. doi: 10.1007/s00439-023-02610-9. Epub 2023 Oct 25.
碱基编辑造血干细胞可拯救患镰状细胞病的小鼠。
Nature. 2021 Jul;595(7866):295-302. doi: 10.1038/s41586-021-03609-w. Epub 2021 Jun 2.
4
Gene therapy using haematopoietic stem and progenitor cells.利用造血干细胞和祖细胞进行基因治疗。
Nat Rev Genet. 2021 Apr;22(4):216-234. doi: 10.1038/s41576-020-00298-5. Epub 2020 Dec 10.
5
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
6
Recapitulation of erythropoiesis in congenital dyserythropoietic anaemia type I (CDA-I) identifies defects in differentiation and nucleolar abnormalities.先天性难治性贫血 I 型(CDA-I)中红细胞生成的综述确定了分化缺陷和核仁异常。
Haematologica. 2021 Nov 1;106(11):2960-2970. doi: 10.3324/haematol.2020.260158.
7
DeepC: predicting 3D genome folding using megabase-scale transfer learning.DeepC:使用兆碱基规模的迁移学习预测 3D 基因组折叠。
Nat Methods. 2020 Nov;17(11):1118-1124. doi: 10.1038/s41592-020-0960-3. Epub 2020 Oct 12.
8
Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.编辑 γ-珠蛋白抑制因子结合位点可恢复胎儿血红蛋白合成并纠正镰状细胞病表型。
Sci Adv. 2020 Feb 12;6(7). doi: 10.1126/sciadv.aay9392. Print 2020 Feb.
9
Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.利用 CRISPR-Cas 核酸酶、碱基编辑器、转座酶和 Prime 编辑器进行基因组编辑。
Nat Biotechnol. 2020 Jul;38(7):824-844. doi: 10.1038/s41587-020-0561-9. Epub 2020 Jun 22.
10
Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity.通过噬菌体辅助进化提高 Cas 结构域兼容性和活性的腺嘌呤碱基编辑器。
Nat Biotechnol. 2020 Jul;38(7):883-891. doi: 10.1038/s41587-020-0453-z. Epub 2020 Mar 16.